More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
Adding Anktiva to BCG led to better responses than BCG alone in people with high-risk bladder cancer who had not yet received BCG, the company said.
A case report details a patient who developed gram-negative sepsis and granulomatous cholestatic hepatitis after intrarenal BCG instillation, highlighting the need for early recognition of systemic ...
Hosted on MSN
The FDA approved Anktiva as the first treatment for one BCG-resistant form of bladder cancer
On October 14, the U.S. Food and Drug Administration announced that Anktiva (nogapendekin alfa inbakicept-pmln), used together with Bacillus Calmette-Guérin, is now approved for adults with ...
TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it at 12 months. The treatment involves six weekly bladder instillations, ...
These five issued patents protect that science at every layer that matters commercially: the compositions of matter, the method of treatment, the wild-type and mutant IL-15 plus BCG compositions, the ...
Original Medicare (parts A and B) generally covers BCG treatments for specific types of bladder cancer when deemed medically necessary by a healthcare team. Part A covers the treatment if it is ...
The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy ...
A research team is shedding new light on Bacillus Calmette-Guerin (BCG), a decades-old bladder cancer treatment, which is also given as vaccine against tuberculosis. The findings could help improve ...
First patients treated in Germany and Austria, with commercial support from Accord Healthcare ; Treatment milestone follows European Commission’s February 2026 conditional marke ...
Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer treatment, with terms extending ...
ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced that five United States patents have been issued to ImmunityBio covering the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results